Real-world Study of Dedifferentiated Liposarcoma Patients in China

NCT06115681 | Completed Results

• 1 other identifier: 1403-0024
• Study Type: observational
• Target: 1,390
• Locations: 1 country
• Sites: 1

Brief Summary

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Conditions

Dedifferentiated Liposarcoma

Outcome Measures

Primary Outcomes (1)

• Cohort 1: Overall Survival

  Overall survival (OS) as an event for each patient in Cohort 1 was defined as the date of death minus the index date or the start day of each line of therapy (LOT). For patients with no record of death, OS was censored at the last activity date before the end of the study period.

  Time from index date until the earliest record of death or end of the study period, up to 10 years.

Secondary Outcomes (8)

• Cohort 1, Cohort 2: Survival After Initial Diagnosis

  Time from initial diagnosis until the earliest record of death or end of the study period, up to 10 years.

• Cohort 1, Cohort 2: Total Number of Treatment Lines

  At index date and during follow-up, up to 10 years.

• Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type

  At index date and during follow-up, up to 10 years

• Cohort 1, Cohort 2: Second Line (2L) of Therapy by Treatment Type

  At index date and during follow-up, up to 10 years

• Cohort 1, Cohort 2: Third Line (3L) of Therapy by Treatment Type

  At index date and during follow-up, up to 10 years

Study Arms (2)

DDLPS patients with 1L treatment at index date (Cohort 1)

Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).

DDLPS patients without 1L treatment at index date (Cohort 2)

Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients who initiated 1L treatment afterwards or patients who received adjuvant and/or neoadjuvant therapy only through follow-up were included in Cohort 2.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013 and confirmed dedifferentiated liposarcoma (DDLPS).

You may qualify if:

• Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
• Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
• At least 18 years old at the date of initial diagnosis.

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (1)

Beijing Jishuitan hospital

Beijing, 102208, China

Location

Related Links

• Related Info

MeSH Terms

Conditions

Liposarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Adipose Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Results Point of Contact

• Title: Boehringer Ingelheim, Call Center
• Organization: Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 27, 2023
• First Posted: November 3, 2023
• Study Start: March 13, 2024
• Primary Completion: May 15, 2024
• Study Completion: May 15, 2024
• Last Updated: July 10, 2025
• Results First Posted: July 10, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)